LOS ANGELES, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming November 7, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period").
If you suffered a loss on your Tandem investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/Tandem-Diabetes-Care-Inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.
On November 2, 2022, Tandem revised its 2022 financial guidance downward, forecasting Non-GAAP sales of $800 to $805 million, down from $835 to $845 million. The Company attributed the revision to increased competition in the diabetes ...
TNDM)>Full story available on Benzinga.com